Observational study shows early dose escalation and longer treatment improve hematologic response in polycythemia vera, suggesting optimized dosing strategies.
Key Points
Evaluate how early dose escalation and treatment duration affect hematologic responses in polycythemia vera patients treated with ropeginterferon alfa-2b.
Observational study across nine hematology centers in Italy.
Data collected on patient demographics, prior treatments, dosing, and hematologic responses over 24 months.
Logistic regression model used to evaluate factors affecting complete hematologic response.
CHR rate increased from 28.7% at 3 months to 56.5% at 24 months.
WBC normalization achieved in 100% of patients by 24 months.
Adverse events led to treatment discontinuation in 15% of patients.